Seroprevalence of hepatitis B and C viruses among children in Kilimanjaro Region, Tanzania

Journal of the Pediatric Infectious Diseases Society

Volumn 2, Issue 4, 2013, Pages 320-326

  Muro, Florida J ^a   Fiorillo, Suzanne P ^b   Sakasaka, Philoteus ^a   Odhiambo, Christopher ^a   Reddy, Elizabeth A ^a,c,d   Cunningham, Coleen K ^c   Buchanan, Ann M ^a,c,d  

^a KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Hepatitis B; Hepatitis C; HIV; Sub Saharan Africa

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEROPREVALENCE; TANZANIA;

EID: 84905120317     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pit018     Document Type: Article

References (42)

1. Wiersma S. Global burden of viral hepatitis. Geneva, Switzerland: World Health Organization; 2010. Available at: http://www. vhpb.org/files/html/Meetings_and_publications/Presentations/ BUDS31.pdf. Accessed April 3, 2013.
2. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. In: Progress Report 2011, UNAIDS, 2011.
3. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163:1138-40.
4. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49(5 Suppl):S138-45.
5. World Health Organization. Worldwide implementation of hepatitis B vaccination of newborns, 2006. Wkly Epidemiol Rec. 2008; 83:429-40.
6. World Health Organziation. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84:405-20.
7. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599-603.
8. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20:992-1000.
9. Committee on Infectious Diseases, American Academy of Pediatrics. Hepatitis C. In: Pickering LK, ed. Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove, IL: American Academy of Pediatrics; 2009: pp 357-60.
10. World Health Organization. Hepatitis C. WHO: Geneva; 2003.
11. Brandt LJ, Mekonen, Tadesse, T, Angala, Maria P, Kalibbala, Madiinah, Mendai, Rejoice, Egodhi, Maria MT. Selection of a 3TC-sparing ART regimen for HBV/HIV co-infected Namibian children with normal ALT as an indicator of immune-tolerant HBV disease. In: Brandt LJ, ed. 4th International Workshop on HIV Pediatrics,Washington, DC: 2012.
12. Ashir G, Rabasa AI, Gofama MM. Study of hepatic functions and hepatitis b surface antigenaemia in Nigerian children with human immunodeficiency virus infection. Niger J Med 2009; 18: 260-2.
13. Rouet F, Chaix ML, Inwoley A, et al. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis 2008; 46:361-6.
14. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es- Salaam, Tanzania. BMC Public Health 2007; 7:338.
15. Nacro B, Dao B, Dahourou H. HBs antigen in children with suspicion of HIV infection. J Trop Pediatr 2001; 47:303-4.
16. Menendez C, Sanchez-Tapias JM, Kahigwa E, et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999; 58:215-20.
17. Meschi S, Schepisi MS, Nicastri E, et al., The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania. J Med Virol 2010; 82:1569-75.
18. Metodi J, Aboud S, Mpembeni R, Munubhi E. Immunity to hepatitis B vaccine in Tanzanian under-5 children. Ann Trop Paediatr 2010; 30:129-36.
19. Mutwa P, Boer KR, Rusine JB, et al. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda [published online ahead of print September 11, 2013]. Pediatr Infect Dis J 2012.
20. Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis 2010; 51:1201-8.
21. Benhamou Y, Bochet M, Thibault V, et al., Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-6.
22. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37:3013-6.
23. Wongprasit P, ManosuthiW, Kiertiburanakul S, Sungkanuparph S. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Patient Care STDS 2010; 24:205-9.
24. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-9.
25. Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011; 31:755-61.
26. World Health Organization. Technical Update on Treatment Optimization: Use of Tenofovir in HIV-Infected Children and Adolescents: A Public Health Perspective. Geneva, Switzerland: World Health Organization; 2012:20.
27. Buchanan AM, Muro FJ, Gratz J, et al. Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. Trop Med Int Health 2010; 15:1011-21.
28. Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr 2010; 54:368-75.
29. Chakraborty R, Rees G, Bourboulia D, et al. Viral coinfections among African children infected with human immunodeficiency virus type 1. Clin Infect Dis 2003; 36:922-4.
30. Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 2012; 206:974-80.
31. Aurpibul L, Lumbiganon P, Kolasaraksa P, et al. HIV and hepatitis B coinfection among perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J 2012; 31:943-7.
32. Neau D, Winnock M, Galpérine T, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004; 5:171-3.
33. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36:1602-5.
34. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195:1437-42.
35. Hepatitis B vaccines. Wkly Epidemiol Rec 2004. 79:255-63.
36. Pippi F, Bracciale L, Stolzuoli L, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med 2008; 9:519-25.
37. Clements CJ, Coghlan B, Creati M, et al. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ 2010; 88: 66-73.
38. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.In: 2010 Revision. Geneva, Switzerland: World Health Organization; 2010.
39. Tran TT. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol (N Y) 2011; 7:511-6.
40. Bzowej NH. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012; 11: 82-9.
41. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-31.
42. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38:575-7.